Atezolizumab,or, Tecentriq

Atezolizumab,or, Tecentriq

Patient-friendly review of Tecentriq or Atezolizumab which is used for treating non-small lung carcinoma (NSCLC), urothelial carcinoma (bladder cancer), and breast cancer. 

Atezolizumab with a trade name Tecentriq received its first approval by the FDA in May 2016. It is a monoclonal antibody and works by targeting specific antigen. Cancer cells can avoid being detected by the T-cells and it does this by using what is called the ‘PD-1 (programmed death receptor-1) pathway’. This causes the T-cells to not be able to recognise the cancer cells as foreign and ignore them, allowing the cancer cells to divide and spread. Tecentriq works by binding onto the PD-L1 which inhibits the PD-1 pathway. This means that T-cells are no longer have suppressed anti-tumour function and able to attack cancer cells. 

Approved by

the Medical Board. 

Click Here

The recommended dosage of Tecentriq for patients with Urothelial carcinoma is 1200 mg and is injected (IV) into patients every 3 weeks for 60 minutes the first time and for 30 minutes second cycle and so on. 

The recommended dosage of Tecentriq as first-line treatment for patients with NSCLC is 1200 mg IV with bevacizumab, paclitaxel, and carboplatin on the first day of each 21-day cycle for a maximum of 4-6 cycles of chemotherapy. 

Common side effects that over 20% of urothelial carcinoma and non-small cell lung cancer patients get are fatigued and decrease in appetite. Furthermore, other reactions can occur such as diarrhea, nausea, constipation, cough, pyrexia and dyspnea.   

Precautions: Because of the mechanism of the drug altering the immune system of the body to attack the cancer cells, there’s a possibility that it could attack the healthy tissues, affecting multiple organs and can become fatal. The potential problems include:

  • Complications in the lungs, liver, colon, hormones and/or kidneys

Other articles that you may find interesting are:

  1. A diet for Chemotherapy
  2. Immunotherapy overview
  3. A to Z Guide to Complementary Therapies

Go to: Return to the CANCERactive drug list

Health Experts
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.